deferiprone has been researched along with Alzheimer Disease in 8 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurodegenerative disorders, such as Alzheimer's disease (AD) and Parkinson disease (PD), can be considered as diverse pathological conditions sharing critical metabolic processes such as protein aggregation and oxidative stress." | 1.37 | Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease. ( Fakih, S; Francis, PT; Gaeta, A; Hider, RC; Kong, XL; Molina-Holgado, F; Salvage, S; Williams, RJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gaeta, A | 1 |
| Molina-Holgado, F | 1 |
| Kong, XL | 1 |
| Salvage, S | 1 |
| Fakih, S | 1 |
| Francis, PT | 1 |
| Williams, RJ | 1 |
| Hider, RC | 1 |
| Xu, P | 1 |
| Zhang, M | 1 |
| Sheng, R | 1 |
| Ma, Y | 1 |
| Zhang, C | 2 |
| Yang, K | 1 |
| Yu, S | 1 |
| Su, J | 1 |
| Yuan, S | 1 |
| Han, J | 1 |
| Chen, Y | 1 |
| Gu, J | 2 |
| Zhou, T | 2 |
| Bai, R | 2 |
| Xie, Y | 2 |
| Jiang, X | 1 |
| Guo, J | 1 |
| Lv, Y | 1 |
| Yao, C | 1 |
| Mi, Z | 1 |
| Shi, Y | 1 |
| Zhang, Y | 2 |
| Guo, T | 2 |
| Ding, Y | 2 |
| Wang, X | 2 |
| Liu, P | 2 |
| Bortolami, M | 1 |
| Pandolfi, F | 1 |
| De Vita, D | 1 |
| Carafa, C | 1 |
| Messore, A | 1 |
| Di Santo, R | 1 |
| Feroci, M | 1 |
| Costi, R | 1 |
| Chiarotto, I | 1 |
| Bagetta, D | 1 |
| Alcaro, S | 1 |
| Colone, M | 1 |
| Stringaro, A | 1 |
| Scipione, L | 1 |
| Telpoukhovskaia, MA | 1 |
| Patrick, BO | 1 |
| Rodríguez-Rodríguez, C | 1 |
| Orvig, C | 1 |
| Prasanthi, JR | 1 |
| Schrag, M | 1 |
| Dasari, B | 1 |
| Marwarha, G | 1 |
| Dickson, A | 1 |
| Kirsch, WM | 1 |
| Ghribi, O | 1 |
8 other studies available for deferiprone and Alzheimer Disease
| Article | Year |
|---|---|
Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cells, Cultured; Humans; Hydrophobic | 2011 |
Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Chelating Agents; Chemistry Techniques, Synt | 2017 |
Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cell Survival; Coumarins; Dose-Response Relationship, | 2019 |
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Ce | 2020 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
New deferiprone derivatives as multi-functional cholinesterase inhibitors: design, synthesis and in vitro evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amino Acid Sequence; Aminopyridines; Catalytic Doma | 2020 |
Exploring the multifunctionality of thioflavin- and deferiprone-based molecules as acetylcholinesterase inhibitors for potential application in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzothiazoles; Binding, Competitive; Blood-Brain Barrier; | 2013 |
Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Aspartic Acid Endopeptidase | 2012 |